- About this Journal ·
- Abstracting and Indexing ·
- Advance Access ·
- Aims and Scope ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
Volume 2011 (2011), Article ID 503028, 8 pages
Methotrexate in Atherogenesis and Cholesterol Metabolism
1Department of Medicine, Division of Translational Medicine, New York University School of Medicine, NBV 16N1, 550 First Avenue, New York, NY 10016, USA
2Inflammation Section, Winthrop Research Institute, Department of Medicine, Winthrop University Hospital, 222 Station Plaza North, Suite 502, Mineola, NY 11501-3893, USA
Received 15 October 2010; Revised 11 January 2011; Accepted 11 January 2011
Academic Editor: M. Jauhiainen
Copyright © 2011 Eric Coomes et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- C. Meune, E. Touzé, L. Trinquart, and Y. Allanore, “High risk of clinical cardiovascular events in rheumatoid arthritis: levels of associations of myocardial infarction and stroke through a systematic review and meta-analysis,” Archives of Cardiovascular Diseases, vol. 103, no. 4, pp. 253–261, 2010.
- M. Feldmann, F. M. Brennan, and R. N. Maini, “Role of cytokines in rheumatoid arthritis,” Annual Review of Immunology, vol. 14, pp. 397–440, 1996.
- C. Tanasescu, C. Jurcut, R. Jurcut, and C. Ginghina, “Vascular disease in rheumatoid arthritis: from subclinical lesions to cardiovascular risk,” European Journal of Internal Medicine, vol. 20, no. 4, pp. 348–354, 2009.
- D. E. Furst, R. W. Ulrich, and C. Varkey-Altamirano, “Nonsteroidal anti-inflammatory drugs, disease modifying antirheumatic drugs, nonopiod analgesics & drugs used in gout,” in Basic and Clinical Pharmacology, B. G. Katzung, S. B. Masters, and A. J. Trevor, Eds., pp. 621–642, McGraw Hill, New York, NY, USA, 11th edition, 2009.
- G. A. FitzGerald, “Coxibs and cardiovascular disease,” New England Journal of Medicine, vol. 351, no. 17, pp. 1709–1711, 2004.
- E. S. L. Chan and B. N. Cronstein, “Methotrexatehow does it really work?” Nature Reviews Rheumatology, vol. 6, no. 3, pp. 175–178, 2010.
- J. Castellsague, C. N. Holick, C. C. Hoffman, V. Gimeno, M. R. Stang, and S. Perez-Gutthann, “Risk of upper gastrointestinal complications associated with cyclooxygenase-2 selective and nonselective nonsteroidal antiinflammatory drugs,” Pharmacotherapy, vol. 29, no. 12, pp. 1397–1407, 2009.
- S. X. Sun, K. Y. Lee, C. T. Bertram, and J. L. Goldstein, “Withdrawal of COX-2 selective inhibitors rofecoxib and valdecoxib: impact on NSAID and gastroprotective drug prescribing and utilization,” Current Medical Research and Opinion, vol. 23, no. 8, pp. 1859–1866, 2007.
- E. S. L. Chan, S. N. Oliver, and B. N. Cronstein, “Immunomodulating pharmaceuticals,” in Clinical Immunology: Principles and Practice, R. R. Rich, T. A. Fleisher, W. T. Shearer, H. W. Schroeder, A. J. Frew, and C. M. Weyand, Eds., pp. 90-1–90-9, Mosby Elsevier, Philadelphia, Pa, USA, 3rd edition, 2008.
- S. L. Westlake, A. N. Colebatch, J. Baird et al., “The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review,” Rheumatology, vol. 49, no. 2, pp. 295–307, 2009.
- A. Reiss, H. Zhang, S. Edelman, et al., “Unraveling coxib atherogenicity: adenosine A2A receptor agonists reverse disruption of cholesterol efflux induced by cyclooxygenase (COX)-2 inhibition,” Inflammation Research, vol. 55, pp. S117–S118, 2006.
- A. B. Reiss, F. Anwar, E. S. L. Chan, and K. Anwar, “Disruption of cholesterol efflux by coxib medications and inflammatory processes: link to increased cardiovascular risk,” Journal of Investigative Medicine, vol. 57, no. 6, pp. 695–702, 2009.
- A. B. Reiss, S. E. Carsons, K. Anwar et al., “Atheroprotective effects of methotrexate on reverse cholesterol transport proteins and foam cell transformation in human THP-1 monocyte/macrophages,” Arthritis and Rheumatism, vol. 58, no. 12, pp. 3675–3683, 2008.
- E. S. L. Chan, H. Zhang, P. Fernandez et al., “Effect of cyclooxygenase inhibition on cholesterol efflux proteins and atheromatous foam cell transformation in THP-1 human macrophages: a possible mechanism for increased cardiovascular risk,” Arthritis Research and Therapy, vol. 9, Article ID R4, 2007.
- V. Ralevic and G. Burnstock, “Receptors for purines and pyrimidines,” Pharmacological Reviews, vol. 50, no. 3, pp. 413–492, 1998.
- M. E. Olah and G. L. Stiles, “The role of receptor structure in determining adenosine receptor activity,” Pharmacology and Therapeutics, vol. 85, no. 2, pp. 55–75, 2000.
- M. C. Montesinos, A. Desai, and B. N. Cronstein, “Suppression of inflammation by low-dose methotrexate is mediated by adenosine A receptor but not A receptor activation in thioglycollate-induced peritonitis,” Arthritis Research and Therapy, vol. 8, no. 2, Article ID R53, 2006.
- J. A. McPherson, K. G. Barringhaus, G. G. Bishop et al., “Adenosine A receptor stimulation reduces inflammation and neointimal growth in a murine carotid ligation model,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 21, no. 5, pp. 791–796, 2001.
- P. A. Borea, S. Gessi, S. Bar-Yehuda, and P. Fishman, “A adenosine receptor: pharmacology and role in disease,” Handbook of Experimental Pharmacology, vol. 193, pp. 297–327, 2009.
- S. Nakav, C. Chaimovitz, Y. Sufaro et al., “Anti-inflammatory preconditioning by agonists of adenosine A1 receptor,” PLoS One, vol. 3, no. 5, Article ID e2107, 2008.
- R. Ross, “Atherosclerosis—an inflammatory disease,” New England Journal of Medicine, vol. 340, no. 2, pp. 115–126, 1999.
- P. Libby, “Changing concepts of atherogenesis,” Journal of Internal Medicine, vol. 247, no. 3, pp. 349–358, 2000.
- A. Von Eckardstein, J. R. Nofer, and G. Assmann, “High density lipoproteins and arteriosclerosis role of cholesterol efflux and reverse cholesterol transport,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 21, no. 1, pp. 13–27, 2001.
- H. S. Kruth, “Macrophage foam cells and atherosclerosis,” Frontiers in Bioscience, vol. 6, pp. D429–D455, 2001.
- R. Ohashi, H. Mu, X. Wang, Q. Yao, and C. Chen, “Reverse cholesterol transport and cholesterol efflux in atherosclerosis,” Monthly Journal of the Association of Physicians, vol. 98, no. 12, pp. 845–856, 2005.
- J. F. Oram and R. M. Lawn, “ABCA1: the gatekeeper for eliminating excess tissue cholesterol,” Journal of Lipid Research, vol. 42, no. 8, pp. 1173–1179, 2001.
- N. Terasaka, N. Wang, L. Yvan-Charvet, and A. R. Tall, “High-density lipoprotein protects macrophages from oxidized low-density lipoprotein-induced apoptosis by promoting efflux of 7-ketocholesterol via ABCG1,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 38, pp. 15093–15098, 2007.
- A. Babiker, O. Andersson, E. Lund et al., “Elimination of cholesterol in macrophages and endothelial cells by the sterol 27-hydroxylase mechanism. Comparison with high density lipoprotein- mediated reverse cholesterol transport,” Journal of Biological Chemistry, vol. 272, no. 42, pp. 26253–26261, 1997.
- X. Wang and D. J. Rader, “Molecular regulation of macrophage reverse cholesterol transport,” Current Opinion in Cardiology, vol. 22, no. 4, pp. 368–372, 2007.
- G. D. Kolovou, D. P. Mikhailidis, K. K. Anagnostopoulou, S. S. Daskalopoulou, and D. V. Cokkinos, “Tangier disease four decades of research: a reflection of the importance of HDL,” Current Medicinal Chemistry, vol. 13, no. 7, pp. 771–782, 2006.
- I. Iatan, K. Alrasadi, I. Ruel, K. Alwaili, and J. Genest, “Effect of ABCA1 mutations on risk for myocardial infarction,” Current Atherosclerosis Reports, vol. 10, no. 5, pp. 413–426, 2008.
- C. Albrecht, S. Soumian, J. S. Amey et al., “ABCA1 expression in carotid atherosclerotic plaques,” Stroke, vol. 35, no. 12, pp. 2801–2806, 2004.
- M. Lee-Rueckert, J. Lappalainen, H. Leinonen, T. Pihlajamaa, M. Jauhiainen, and P. T. Kovanen, “Acidic extracellular environments strongly impair ABCA1-mediated cholesterol efflux from human macrophage foam cells,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 30, no. 9, pp. 1766–1772, 2010.
- M. Naghavi, R. John, S. Naguib et al., “pH heterogeneity of human and rabbit atherosclerotic plaques; a new insight into detection of vulnerable plaque,” Atherosclerosis, vol. 164, no. 1, pp. 27–35, 2002.
- A. B. Reiss and A. D. Glass, “Atherosclerosis: immune and inflammatory aspects,” Journal of Investigative Medicine, vol. 54, no. 3, pp. 123–131, 2006.
- V. M. Olkkonen and M. Lehto, “Oxysterols and oxysterol binding proteins: role in lipid metabolism and atherosclerosis,” Annals of Medicine, vol. 36, no. 8, pp. 562–572, 2004.
- I. Björkhem and U. Diczfalusy, “Oxysterols: friends, foes, or just fellow passengers?” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 22, no. 5, pp. 734–742, 2002.
- I. Bjorkhem, O. Andersson, U. Diczfalusy et al., “Atherosclerosis and sterol 27-hydroxylase: evidence for a role of this enzyme in elimination of cholesterol from human macrophages,” Proceedings of the National Academy of Sciences of the United States of America, vol. 91, no. 18, pp. 8592–8596, 1994.
- A. Babiker, S. Dzeletovic, B. Wiklund et al., “Patients with atherosclerosis may have increased circulating levels of 27-hydroxycholesterol and cholestenoic acid,” Scandinavian Journal of Clinical and Laboratory Investigation, vol. 65, no. 5, pp. 365–376, 2005.
- X. Fu, J. G. Menke, Y. Chen et al., “27-hydroxycholesterol is an endogenous ligand for liver X receptor in cholesterol-loaded cells,” Journal of Biological Chemistry, vol. 276, no. 42, pp. 38378–38387, 2001.
- S. Murthy, E. Born, S. N. Mathur, and F. J. Field, “LXR/RXR activation enhances basolateral efflux of cholesterol in CaCo-2 cells,” Journal of Lipid Research, vol. 43, no. 7, pp. 1054–1064, 2002.
- P. A. Edwards, M. A. Kennedy, and P. A. Mak, “LXRs; Oxysterol-activated nuclear receptors that regulate genes controlling lipid homeostasis,” Vascular Pharmacology, vol. 38, no. 4, pp. 249–256, 2002.
- A. B. Reiss, “Effects of inflammation on cholesterol metabolism: impact on systemic lupus erythematosus,” Current Rheumatology Reports, vol. 11, no. 4, pp. 255–260, 2009.
- J. George, D. Harats, B. Gilburd, Y. Levy, P. Langevitz, and Y. Shoenfeld, “Atherosclerosis-related markers in systemic lupus erythematosus patients: the role of humoral immunity in enhanced atherogenesis,” Lupus, vol. 8, no. 3, pp. 220–226, 1999.
- G. Virella and M. F. Lopes-Virella, “Atherogenesis and the humoral immune response to modified lipoproteins,” Atherosclerosis, vol. 200, no. 2, pp. 239–246, 2008.
- A. B. Reiss, M. M. Rahman, E. S. L. Chan, M. C. Montesinos, N. W. Awadallah, and B. N. Cronstein, “Adenosine A receptor occupancy stimulates expression of proteins involved in reverse cholesterol transport and inhibits foam cell formation in macrophages,” Journal of Leukocyte Biology, vol. 76, no. 3, pp. 727–734, 2004.
- A. B. Reiss, N. W. Awadallah, S. Malhotra et al., “Immune complexes and IFN-γ decrease cholesterol 27-hydroxylase in human arterial endothelium and macrophages,” Journal of Lipid Research, vol. 42, no. 11, pp. 1913–1922, 2001.
- X. R. Hao, D. L. Cao, Y. W. Hu et al., “IFN-γ down-regulates ABCA1 expression by inhibiting LXRα in a JAK/STAT signaling pathway-dependent manner,” Atherosclerosis, vol. 203, no. 2, pp. 417–428, 2009.
- K. E. Barnholt, R. S. Kota, H. H. Aung, and J. C. Rutledge, “Adenosine blocks IFN-γ-induced phosphorylation of STAT1 on serine 727 to reduce macrophage activation,” Journal of Immunology, vol. 183, no. 10, pp. 6767–6777, 2009.
- J. E. McLaren and D. P. Ramji, “Interferon gamma: a master regulator of atherosclerosis,” Cytokine and Growth Factor Reviews, vol. 20, no. 2, pp. 125–135, 2009.
- J. S. Nair, C. J. DaFonseca, A. Tjernberg et al., “Requirement of and CaMKII for Stat1 Ser-727 phosphorylation in response to IFN-γ,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 9, pp. 5971–5976, 2002.
- R. B. M. Landewé, B. E. E. M. Van Den Borne, F. C. Breedveld, and B. A. C. Dijkmans, “Methotrexate effects in patients with rheumatoid arthritis with cardiovascular comorbidity,” Lancet, vol. 355, no. 9215, pp. 1616–1617, 2000.
- J. Lynge, G. Schulte, N. Nordsborg, B. B. Fredholm, and Y. Hellsten, “Adenosine A receptors modulate cAMP levels and induce CREB but not ERK1/2 and p38 phosphorylation in rat skeletal muscle cells,” Biochemical and Biophysical Research Communications, vol. 307, no. 1, pp. 180–187, 2003.
- T. C. Bingham, E. A. Fisher, S. Parathath, A. B. Reiss, E. S. Chan, and B. N. Cronstein, “A2A adenosine receptor stimulation decreases foam cell formation by enhancing ABCA1-dependent cholesterol efflux,” Journal of Leukocyte Biology, vol. 87, no. 4, pp. 683–690, 2010.
- J. L. Bos, “Epac: a new cAMP target and new avenues in cAMP research,” Nature Reviews Molecular Cell Biology, vol. 4, no. 9, pp. 733–738, 2003.
- L. Martin, S. C. Pingle, D. M. Hallam, L. P. Rybak, and V. Ramkumar, “Activation of the adenosine A receptor in RAW 264.7 cells inhibits lipopolysaccharide-stimulated tumor necrosis factor-α release by reducing calcium-dependent activation of nuclear factor-κB and extracellular signal-regulated kinase 1/2,” Journal of Pharmacology and Experimental Therapeutics, vol. 316, no. 1, pp. 71–78, 2006.
- P. M. Ridker, “Testing the inflammatory hypothesis of atherothrombosis: scientific rationale for the cardiovascular inflammation reduction trial (CIRT),” Journal of Thrombosis and Haemostasis, vol. 7, no. 1, pp. 332–339, 2009.